Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Optic Pathway Glioma in Type 1 Neurofibromatosis: Review of Its Pathogenesis, Diagnostic Assessment, and Treatment Recommendations.

Cassina M, Frizziero L, Opocher E, Parrozzani R, Sorrentino U, Viscardi E, Miglionico G, Midena E, Clementi M, Trevisson E.

Cancers (Basel). 2019 Nov 14;11(11). pii: E1790. doi: 10.3390/cancers11111790. Review.

3.

Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.

Freret ME, Gutmann DH.

J Neurosci Res. 2019 Jan;97(1):45-56. doi: 10.1002/jnr.24250. Epub 2018 Apr 28. Review.

4.

Natural history of optic pathway gliomas in a cohort of unselected patients affected by Neurofibromatosis 1.

Trevisson E, Cassina M, Opocher E, Vicenzi V, Lucchetta M, Parrozzani R, Miglionico G, Mardari R, Viscardi E, Midena E, Clementi M.

J Neurooncol. 2017 Sep;134(2):279-287. doi: 10.1007/s11060-017-2517-6. Epub 2017 Jun 2.

PMID:
28577031
5.

Systematic MRI in NF1 children under six years of age for the diagnosis of optic pathway gliomas. Study and outcome of a French cohort.

Blanchard G, Lafforgue MP, Lion-François L, Kemlin I, Rodriguez D, Castelnau P, Carneiro M, Meyer P, Rivier F, Barbarot S, Chaix Y; NF France network.

Eur J Paediatr Neurol. 2016 Mar;20(2):275-281. doi: 10.1016/j.ejpn.2015.12.002. Epub 2015 Dec 17.

6.

Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations.

Listernick R, Ferner RE, Liu GT, Gutmann DH.

Ann Neurol. 2007 Mar;61(3):189-98. Review.

7.

Visual outcomes after chemotherapy for optic pathway glioma in children with and without neurofibromatosis type 1: results of the International Society of Paediatric Oncology (SIOP) Low-Grade Glioma 2004 trial UK cohort.

Falzon K, Drimtzias E, Picton S, Simmons I.

Br J Ophthalmol. 2018 Oct;102(10):1367-1371. doi: 10.1136/bjophthalmol-2017-311305. Epub 2018 Jan 17.

PMID:
29343527
8.

Identification of Mutation Regions on NF1 Responsible for High- and Low-Risk Development of Optic Pathway Glioma in Neurofibromatosis Type I.

Xu M, Xiong H, Han Y, Li C, Mai S, Huang Z, Ai X, Guo Z, Zeng F, Guo Q.

Front Genet. 2018 Jul 24;9:270. doi: 10.3389/fgene.2018.00270. eCollection 2018.

9.

Clustering of mutations in the 5' tertile of the NF1 gene in Slovakia patients with optic pathway glioma.

Bolcekova A, Nemethova M, Zatkova A, Hlinkova K, Pozgayova S, Hlavata A, Kadasi L, Durovcikova D, Gerinec A, Husakova K, Pavlovicova Z, Holobrada M, Kovacs L, Ilencikova D.

Neoplasma. 2013;60(6):655-65. doi: 10.4149/neo_2013_084.

PMID:
23906300
10.

Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1.

Evans DGR, Salvador H, Chang VY, Erez A, Voss SD, Schneider KW, Scott HS, Plon SE, Tabori U.

Clin Cancer Res. 2017 Jun 15;23(12):e46-e53. doi: 10.1158/1078-0432.CCR-17-0589. Review.

11.

Brain Tumors in NF1 Children: Influence on Neurocognitive and Behavioral Outcome.

Taddei M, Erbetta A, Esposito S, Saletti V, Bulgheroni S, Riva D.

Cancers (Basel). 2019 Nov 11;11(11). pii: E1772. doi: 10.3390/cancers11111772.

12.

Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome.

King A, Listernick R, Charrow J, Piersall L, Gutmann DH.

Am J Med Genet A. 2003 Oct 1;122A(2):95-9.

PMID:
12955759
13.

Growth hormone excess in children with neurofibromatosis type-1 and optic glioma.

Cambiaso P, Galassi S, Palmiero M, Mastronuzzi A, Del Bufalo F, Capolino R, Cacchione A, Buonuomo PS, Gonfiantini MV, Bartuli A, Cappa M, Macchiaiolo M.

Am J Med Genet A. 2017 Sep;173(9):2353-2358. doi: 10.1002/ajmg.a.38308. Epub 2017 Jun 20.

PMID:
28631895
14.

Clinical Presentation and Outcome of Patients With Optic Pathway Glioma.

Robert-Boire V, Rosca L, Samson Y, Ospina LH, Perreault S.

Pediatr Neurol. 2017 Oct;75:55-60. doi: 10.1016/j.pediatrneurol.2017.06.019. Epub 2017 Jul 6.

PMID:
28847625
15.

Risk of Optic Pathway Glioma in Neurofibromatosis Type 1: No Evidence of Genotype-Phenotype Correlations in A Large Independent Cohort.

Melloni G, Eoli M, Cesaretti C, Bianchessi D, Ibba MC, Esposito S, Scuvera G, Morcaldi G, Micheli R, Piozzi E, Avignone S, Chiapparini L, Pantaleoni C, Natacci F, Finocchiaro G, Saletti V.

Cancers (Basel). 2019 Nov 21;11(12). pii: E1838. doi: 10.3390/cancers11121838.

16.

Estrogen activation of microglia underlies the sexually dimorphic differences in Nf1 optic glioma-induced retinal pathology.

Toonen JA, Solga AC, Ma Y, Gutmann DH.

J Exp Med. 2017 Jan;214(1):17-25. doi: 10.1084/jem.20160447. Epub 2016 Dec 6.

17.

Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients.

Segal L, Darvish-Zargar M, Dilenge ME, Ortenberg J, Polomeno RC.

J AAPOS. 2010 Apr;14(2):155-8. doi: 10.1016/j.jaapos.2009.11.020.

PMID:
20451859
18.

Use of Optical Coherence Tomography to Detect Retinal Nerve Fiber Loss in Children With Optic Pathway Glioma.

Zahavi A, Toledano H, Cohen R, Sella S, Luckman J, Michowiz S, Goldenberg-Cohen N.

Front Neurol. 2018 Dec 20;9:1102. doi: 10.3389/fneur.2018.01102. eCollection 2018.

19.

Optic Pathway Gliomas in Neurofibromatosis Type 1.

Campen CJ, Gutmann DH.

J Child Neurol. 2018 Jan;33(1):73-81. doi: 10.1177/0883073817739509. Review.

20.

Manifestations and Treatment of Adult-onset Symptomatic Optic Pathway Glioma in Neurofibromatosis Type 1.

Mehlan J, Schüttauf F, Salamon JM, Kordes U, Friedrich RE, Mautner VF.

Anticancer Res. 2019 Feb;39(2):827-831. doi: 10.21873/anticanres.13181.

PMID:
30711963

Supplemental Content

Support Center